[go: up one dir, main page]

NO20022633D0 - 4-Pyrimidinyl-N-acyl-L-fenylalaniner - Google Patents

4-Pyrimidinyl-N-acyl-L-fenylalaniner

Info

Publication number
NO20022633D0
NO20022633D0 NO20022633A NO20022633A NO20022633D0 NO 20022633 D0 NO20022633 D0 NO 20022633D0 NO 20022633 A NO20022633 A NO 20022633A NO 20022633 A NO20022633 A NO 20022633A NO 20022633 D0 NO20022633 D0 NO 20022633D0
Authority
NO
Norway
Prior art keywords
pyrimidinyl
phenylalanine
acyl
Prior art date
Application number
NO20022633A
Other languages
English (en)
Other versions
NO20022633L (no
NO322866B1 (no
Inventor
Achyutharao Sidduri
Jefferson Wright Tilley
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20022633D0 publication Critical patent/NO20022633D0/no
Publication of NO20022633L publication Critical patent/NO20022633L/no
Publication of NO322866B1 publication Critical patent/NO322866B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20022633A 1999-12-06 2002-06-04 4-Pyrimidinyl-N-acyl-L-fenylalaniner, anvendelse av disse som medikamenter og for behandling av sykdom, farmasoytiske preparater inneholdende slike, fremgangsmate for fremstilling av farmasoytisk preparat inneholdende disse og anvendelse av disse for fremstilling av medikament for behandling av sykdommer. NO322866B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16908999P 1999-12-06 1999-12-06
PCT/EP2000/011884 WO2001042225A2 (en) 1999-12-06 2000-11-28 4-pyrimidinyl-n-acyl-l-phenylalanines

Publications (3)

Publication Number Publication Date
NO20022633D0 true NO20022633D0 (no) 2002-06-04
NO20022633L NO20022633L (no) 2002-06-04
NO322866B1 NO322866B1 (no) 2006-12-18

Family

ID=22614222

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022633A NO322866B1 (no) 1999-12-06 2002-06-04 4-Pyrimidinyl-N-acyl-L-fenylalaniner, anvendelse av disse som medikamenter og for behandling av sykdom, farmasoytiske preparater inneholdende slike, fremgangsmate for fremstilling av farmasoytisk preparat inneholdende disse og anvendelse av disse for fremstilling av medikament for behandling av sykdommer.

Country Status (35)

Country Link
EP (1) EP1237878B1 (no)
JP (1) JP3824935B2 (no)
KR (1) KR100522344B1 (no)
CN (1) CN1218943C (no)
AR (1) AR034401A1 (no)
AT (1) ATE357433T1 (no)
AU (1) AU783348B2 (no)
BR (1) BR0016195A (no)
CA (1) CA2392570C (no)
CO (1) CO5080772A1 (no)
CY (1) CY1106626T1 (no)
CZ (1) CZ303435B6 (no)
DE (1) DE60034061T2 (no)
DK (1) DK1237878T3 (no)
EG (1) EG24361A (no)
ES (1) ES2282162T3 (no)
HK (1) HK1054384B (no)
HR (1) HRP20020468B1 (no)
HU (1) HU229105B1 (no)
IL (2) IL149617A0 (no)
JO (1) JO2283B1 (no)
MA (1) MA26850A1 (no)
MX (1) MXPA02005564A (no)
MY (1) MY126972A (no)
NO (1) NO322866B1 (no)
NZ (1) NZ518828A (no)
PE (1) PE20010961A1 (no)
PL (1) PL207160B1 (no)
PT (1) PT1237878E (no)
RS (1) RS50371B (no)
RU (1) RU2266901C2 (no)
SI (1) SI1237878T1 (no)
TW (1) TWI256387B (no)
WO (1) WO2001042225A2 (no)
ZA (1) ZA200203533B (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
EP1288205B1 (en) * 2000-08-18 2011-02-02 Ajinomoto Co., Inc. Novel phenylalanine derivatives
AR033765A1 (es) * 2001-05-22 2004-01-07 Syngenta Participations Ag Procedimiento para la preparacion de derivados 3-alquil-3h-isobenzofuran-1-ona 7-sustituidos.
EP1454898A4 (en) * 2001-12-13 2006-12-13 Ajinomoto Kk NEW PHENYL ALANIDE DERIVATIVES
RU2390520C2 (ru) 2003-12-22 2010-05-27 Адзиномото Ко., Инк. Новые производные фенилаланина
US7618981B2 (en) * 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
RU2007109601A (ru) * 2004-08-16 2008-09-27 Мерк энд Ко., Инк. (US) Антагонисты vla-4
JP4784224B2 (ja) 2004-09-24 2011-10-05 味の素株式会社 糖鎖転移方法および糖鎖転移酵素
WO2007060408A2 (en) * 2005-11-23 2007-05-31 Astrazeneca Ab L-phenylalanine derivatives and their use as integrin antagonists
AR059224A1 (es) * 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
EP1984330A1 (en) * 2006-02-09 2008-10-29 AstraZeneca AB Chemical compounds
AU2007262147B2 (en) * 2006-06-19 2012-08-16 Toray Industries, Inc. Therapeutic or prophylactic agent for multiple sclerosis
PL2368882T3 (pl) 2007-09-17 2015-04-30 Abbvie Bahamas Ltd Pirymidyny o działaniu przeciw zakaźnym oraz ich zastosowania
RU2542099C2 (ru) 2007-09-17 2015-02-20 Эббви Бахамаз Лтд. N-фенил-диоксо-гидропиримидины, используемые в качестве ингибитора вируса гепатита с (hcv)
CN101801935B (zh) 2007-09-17 2014-12-03 艾伯维巴哈马有限公司 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物
CN102264747B (zh) * 2008-12-22 2014-09-24 Icl-Ip美国公司 基于水混溶性溶剂的二磷酸酯纯化用方法
US9216952B2 (en) 2010-03-23 2015-12-22 Abbvie Inc. Process for preparing antiviral compound
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
EP3415504A1 (en) 2010-07-16 2018-12-19 AbbVie Ireland Unlimited Company Process for preparing antiviral compounds
WO2012009698A1 (en) 2010-07-16 2012-01-19 Abbott Laboratories Phosphine ligands for catalytic reactions
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
KR20140127234A (ko) * 2012-01-27 2014-11-03 에프. 호프만-라 로슈 아게 Ｖｌａ-4 발현 세포로의 표적화된 전달을 위한 인테그린 안타고니스트 접합체
US9447035B2 (en) * 2012-01-27 2016-09-20 Hoffmann-La Roche Inc. Integrin antagonist conjugates for targeted delivery to cells expressing VLA-4
AU2014324426A1 (en) 2013-09-30 2016-04-21 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
EP3064491B1 (en) 2013-10-29 2020-01-08 EA Pharma Co., Ltd. Sulfonamide derivative and medicinal use thereof
JP2018515424A (ja) 2015-03-10 2018-06-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗アルファｖベータ１インテグリン阻害剤及び使用方法
CA3115830C (en) 2018-10-30 2023-09-12 Gilead Sciences, Inc. Compounds for inhibition of .alpha.4.beta.7 integrin
WO2020092383A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
KR102641718B1 (ko) 2018-10-30 2024-02-29 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 이미다조피리딘 유도체
IL282545B2 (en) 2018-10-30 2025-04-01 Gilead Sciences Inc Quinoline derivatives as alpha4beta7 integrin inhibitors
KR102908219B1 (ko) 2019-08-14 2026-01-08 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH516578A (de) * 1967-11-02 1971-12-15 Bayer Ag Verfahren zur Herstellung von heterocyclische Acylaminogruppen enthaltenden Arylsulfonylharnstoffen mit blutdrucksenkender Wirkung
JP2001517245A (ja) * 1997-05-29 2001-10-02 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としてのビアリールアルカン酸類
EP1001764A4 (en) * 1997-05-29 2005-08-24 Merck & Co Inc HETEROCYCLIC AMIDE COMPOUNDS AS INHIBITORS OF CELL ADHESION
DE69824183T2 (de) * 1997-08-22 2005-04-21 Hoffmann La Roche N-alkanoylphenylalaninderivate
BR9811988A (pt) * 1997-08-22 2000-09-05 Hoffmann La Roche Derivados de n-alcanoilfenilalanina
CA2357781A1 (en) * 1999-01-22 2000-07-27 Elan Pharmaceuticals, Inc. Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4

Also Published As

Publication number Publication date
NZ518828A (en) 2004-03-26
JP3824935B2 (ja) 2006-09-20
MA26850A1 (fr) 2004-12-20
JO2283B1 (en) 2005-09-12
IL149617A (en) 2007-10-31
CO5080772A1 (es) 2001-09-25
WO2001042225A2 (en) 2001-06-14
DE60034061T2 (de) 2007-12-13
CY1106626T1 (el) 2012-01-25
HRP20020468A2 (en) 2004-04-30
JP2003516396A (ja) 2003-05-13
CN1218943C (zh) 2005-09-14
HK1054384A1 (en) 2003-11-28
ATE357433T1 (de) 2007-04-15
HK1054384B (zh) 2005-12-09
WO2001042225A3 (en) 2002-02-21
AU783348B2 (en) 2005-10-20
ZA200203533B (en) 2003-08-04
HRP20020468B1 (en) 2009-02-28
HUP0204081A3 (en) 2003-07-28
EG24361A (en) 2009-03-04
IL149617A0 (en) 2002-11-10
CA2392570C (en) 2010-05-11
CZ303435B6 (cs) 2012-09-12
WO2001042225A8 (en) 2002-06-06
PE20010961A1 (es) 2001-09-26
RU2266901C2 (ru) 2005-12-27
TWI256387B (en) 2006-06-11
HU229105B1 (en) 2013-07-29
CN1407972A (zh) 2003-04-02
MXPA02005564A (es) 2002-09-02
NO20022633L (no) 2002-06-04
RS50371B (sr) 2009-11-10
AU2669601A (en) 2001-06-18
CA2392570A1 (en) 2001-06-14
BR0016195A (pt) 2002-08-13
KR20020063906A (ko) 2002-08-05
DK1237878T3 (da) 2007-07-30
NO322866B1 (no) 2006-12-18
YU40402A (sh) 2005-03-15
ES2282162T3 (es) 2007-10-16
AR034401A1 (es) 2004-02-25
PL357601A1 (en) 2004-07-26
EP1237878A2 (en) 2002-09-11
CZ20022351A3 (cs) 2003-04-16
KR100522344B1 (ko) 2005-10-20
PL207160B1 (pl) 2010-11-30
PT1237878E (pt) 2007-06-18
EP1237878B1 (en) 2007-03-21
SI1237878T1 (sl) 2007-08-31
HUP0204081A2 (en) 2003-05-28
MY126972A (en) 2006-11-30
DE60034061D1 (de) 2007-05-03
RU2002117422A (ru) 2004-03-10

Similar Documents

Publication Publication Date Title
DE50010505D1 (de) Gurtaufrollersystem
DE122007000064I2 (de) Erythropoietinkonjugate
DE19983871T1 (de) Fönvorrichtung
DE60001240D1 (de) Laserdepiliergerät
DE50002834D1 (de) Handstempel
DE60034061D1 (de) 4-pyrimidinyl-n-acyl-l-phenylanine
ATE297895T1 (de) 4-pyridinyl-n-acyl-l-phenylalanine
DE60001894D1 (de) Busschienenverbindungsstruktur
DE50015451D1 (de) Spülwannensystem
DE60001649D1 (de) Ziprasidonsuspension
DE50007953D1 (de) Beleuchtungsanordung
DE59910286D1 (de) Kniehebel-spannvorrichtung
DE50008613D1 (de) Sicherungsring
DE50016100D1 (de) Gabtriebs
DE50000805D1 (de) Aufsitzspanner
DE50012482D1 (de) Tibiamarknagel
DE60001471D1 (de) 4-Hydroxyisothiazolverbindungen
DE50003259D1 (de) Textilie
DE60000940D1 (de) Wälzlagerstahl
DE50006013D1 (de) Anschlagpuffer
DE59906520D1 (de) Exzenterzahnradgetriebe
DE19983890T1 (de) Ventiltaktgebungsjustiereinrichtung
DE50008429D1 (de) Kraftstofffraktioniereinrichtung
DE50001640D1 (de) Nahfeldoptische untersuchungsvorrichtung
DE50006759D1 (de) Piperidinalkohole

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees